Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
UCB SA (UCBJF) Q4 2019 Earnings Conference Call February 20, 2020 08:00 AM ET Company Participants Antje Witte - VP, IR Jean-Christophe Tellier - CEO & Executive Director Emmanuel Caeymaex - EVP & Head, Immunology Patient Value Unit Detlef Thielgen - CFO & EVP Cha...
The following slide deck was published by UCB SA in conjunction with their 2019 Q4 earnings Read more ...
Amgen (NASDAQ: AMGN ) and UCB ( OTCPK:UCBJY ) announces that the European Commission (EC) has granted marketing authorization for EVENITY (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. More news on: Amgen Inc., UCB SA, UCB SA...
- New survey reveals that 65% of women with osteoporosis believe their condition is being neglected 1 - 58% said that the impact of osteoporosis/fragility fractures is not fully understood or appreciated by their healthcare authority , with four in five (83%) agreeing that t...
THOUSAND OAKS, Calif. and BRUSSELS , Dec. 11, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY ® (romosozumab) for the treatment of severe osteoporosis i...
- Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy d...
BRUSSELS , Dec. 6, 2019 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from the Phase 3 active-controlled BE SURE study. BE SURE compared the investigational IL-17A and IL-...
ATLANTA , Dec. 5, 2019 /PRNewswire/ -- UCB today announced 14 posters have been selected for presentation at this year's American Epilepsy Society Meeting, taking place in Baltimore, Maryland , December 6-10 . The UCB scientific program includes the presentation of clinical data de...
ATLANTA , Nov. 25, 2019 /PRNewswire/ -- UCB announced today that NAYZILAM® (midazolam) nasal spray CIV will be available in retail pharmacies on December 2, 2019 , for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acu...
BRUSSELS , Nov. 15, 2019 /PRNewswire/ -- Regulated Information – Inside Information – UCB, a global biopharmaceutical company, today announced positive results from BE READY, the second of three Phase 3 studies this year to report findings on the investigational tre...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price! PR Newswire Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi announce the fu...
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...